NCT04269954

The Efficacy and Safety of Batroxobin Combined With Anticoagulation in Cerebral Venous Sinus Thrombosis

• Status: Unknown
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 60 (estimated)
• Sponsor: Capital Medical University · Academic / Other
• Sex: All
• Age: 18 Years – 80 Years
• Healthy volunteers: Not accepted

Summary

Our previous clinical case observations showed that batroxobin combined with anticoagulation therapy can improve the sinus recanalization rate in patients with CVST, shorten the hospital stay, and increase the neurological score of patients. Its main mechanism is to inhibit thrombosis after reducing fibrinogen, and to dissolve thrombus. To further explore the safety of batroxobin combined with anticoagulation therapy for CVST, an open-label, randomized controlled (1: 1), single-center, prospective study was used. Further study on the safety and effectiveness of batroxobin combined with anticoagulation for CVST.

Conditions

• Cerebral Venous Sinus Thrombosis
• Batroxobin

Interventions

Type	Name	Description
DRUG	Batroxobin combined with low molecular weight heparin	Standard treatment of Batroxobin combined with low molecular weight heparin

Timeline

• Start date: 2020-03-01
• Primary completion: 2021-03-01
• Completion: 2021-12-01
• First posted: 2020-02-17
• Last updated: 2020-02-17

Locations

1 site across 1 country: China